Jeremy R Chapman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10576764/publications.pdf

Version: 2024-02-01

162 papers	13,305 citations	34105 52 h-index	22832 112 g-index
165 all docs	165 docs citations	165 times ranked	10408 citing authors

#	Article	IF	Citations
1	The Natural History of Chronic Allograft Nephropathy. New England Journal of Medicine, 2003, 349, 2326-2333.	27.0	1,748
2	Cancer Incidence Before and After Kidney Transplantation. JAMA - Journal of the American Medical Association, 2006, 296, 2823.	7.4	953
3	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation, 2013, 95, 19-47.	1.0	679
4	KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney International, 2010, 77, 299-311.	5.2	675
5	Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ: British Medical Journal, 2005, 331, 810.	2.3	482
6	Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology. Transplantation, 2004, 78, 557-565.	1.0	419
7	Chronic Renal Allograft Dysfunction. Journal of the American Society of Nephrology: JASN, 2005, 16, 3015-3026.	6.1	382
8	Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials. Transplantation, 2006, 81, 1234-1248.	1.0	305
9	Chronic Allograft Nephropathy: Current Concepts and Future Directions. Transplantation, 2006, 81, 643-654.	1.0	294
10	PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATION. Transplantation, 1995, 59, 1683-1689.	1.0	263
11	Association of CKD and Cancer Risk in Older People. Journal of the American Society of Nephrology: JASN, 2009, 20, 1341-1350.	6.1	251
12	EFFECT OF HISTOLOGICAL DAMAGE ON LONG-TERM KIDNEY TRANSPLANT OUTCOME. Transplantation, 2001, 71, 515-523.	1.0	236
13	How can we achieve global equity in provision of renal replacement therapy?. Bulletin of the World Health Organization, 2008, 86, 229-237.	3.3	230
14	Natural History, Risk Factors, and Impact of Subclinical Rejection in Kidney Transplantation. Transplantation, 2004, 78, 242-249.	1.0	227
15	Cancer in the Transplant Recipient. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015677-a015677.	6.2	221
16	Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials1. Transplantation, 2004, 77, 166-176.	1.0	208
17	The pattern of excess cancer in dialysis and transplantation. Nephrology Dialysis Transplantation, 2009, 24, 3225-3231.	0.7	174
18	Comparative Survival and Economic Benefits of Deceased Donor Kidney Transplantation and Dialysis in People with Varying Ages and Co-Morbidities. PLoS ONE, 2012, 7, e29591.	2.5	158

#	Article	IF	Citations
19	Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ: British Medical Journal, 2010, 340, c570-c570.	2.3	149
20	Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet, The, 2016, 388, 983-993.	13.7	148
21	Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. The Cochrane Library, 2005, , CD003961.	2.8	144
22	Cancer in kidney transplant recipients. Nature Reviews Nephrology, 2018, 14, 508-520.	9.6	137
23	Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology. Transplantation, 2016, 100, 1723-1731.	1.0	136
24	The Motivations and Experiences of Living Kidney Donors: A Thematic Synthesis. American Journal of Kidney Diseases, 2012, 60, 15-26.	1.9	123
25	Reduced Estimated GFR and Cancer Mortality. American Journal of Kidney Diseases, 2014, 63, 23-30.	1.9	121
26	Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood, 2009, 114, 630-637.	1.4	115
27	Clinical Practice Guidelines on Wait-Listing for Kidney Transplantation. Transplantation, 2012, 94, 703-713.	1.0	115
28	The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. American Journal of Transplantation, 2018, 18, 364-376.	4.7	113
29	CHARACTERIZATION OF LYMPHOCYTOTOXIC ANTIBODIES CAUSING A POSITIVE CROSSMATCH IN RENAL TRANSPLANTATION. Transplantation, 1989, 48, 953-958.	1.0	111
30	PREDICTORS OF RENAL TRANSPLANT HISTOLOGY AT THREE MONTHS. Transplantation, 1999, 67, 1222-1230.	1.0	111
31	Delta Analysis of Posttransplantation Tubulointerstitial Damage. Transplantation, 2004, 78, 434-441.	1.0	102
32	Treatment of Subclinical Rejection Diagnosed by Protocol Biopsy of Kidney Transplants. Transplantation, 2006, 82, 36-42.	1.0	97
33	Screening and Follow-Up of Living Kidney Donors: A Systematic Review of Clinical Practice Guidelines. Transplantation, 2011, 92, 962-972.	1.0	97
34	DIABETIC NEUROPATHY AFTER PANCREAS TRANSPLANTATION: DETERMINANTS OF RECOVERY. Transplantation, 1997, 63, 830-838.	1.0	97
35	Cancer Screening in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, S87-S100.	4.5	94
36	Cancers after renal transplantation. Transplantation Reviews, 2008, 22, 141-149.	2.9	90

#	Article	IF	Citations
37	Diabetic retinopathy after combined kidneyâ€“pancreas transplantation. Clinical Transplantation, 1999, 13, 356-362.	1.6	85
38	Belatacept for kidney transplant recipients. The Cochrane Library, 2014, 2014, CD010699.	2.8	82
39	Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. Journal of the American Society of Nephrology: JASN, 2019, 30, 471-480.	6.1	81
40	The clinical and pathological significance of borderline T cellâ€“mediated rejection. American Journal of Transplantation, 2019, 19, 1452-1463.	4.7	75
41	Immunosuppression and Other Risk Factors for Lip Cancer after Kidney Transplantation. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 561-569.	2.5	73
42	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. American Journal of Kidney Diseases, 2015, 66, 212-222.	1.9	73
43	Monoclonal and Polyclonal Antibody Therapy for Treating Acute Rejection in Kidney Transplant Recipients: A Systematic Review of Randomized Trial Data. Transplantation, 2006, 81, 953-965.	1.0	71
44	HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 875-883.	4.5	71
45	ORAL CYCLOSPORINE BUT NOT TACROLIMUS REDUCES RENAL TRANSPLANT BLOOD FLOW. Transplantation, 2004, 77, 1457-1459.	1.0	69
46	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. Transplantation, 2017, 101, 1875-1886.	1.0	68
47	Cutaneous Melanoma Is Related to Immune Suppression in Kidney Transplant Recipients. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2297-2303.	2.5	66
48	Evolution and Pathophysiology of Renal-Transplant Glomerulosclerosis. Transplantation, 2004, 78, 461-468.	1.0	63
49	The KDIGO Clinical Practice Guidelines for the Care of Kidney Transplant Recipients. Transplantation, 2010, 89, 644-645.	1.0	61
50	Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. The Cochrane Library, 2006, , CD004290.	2.8	58
51	Compliance: the patient, the doctor, and the medication?. Transplantation, 2004, 77, 782-786.	1.0	56
52	Acute Rejection, T-Cellâ€“Depleting Antibodies, and Cancer After Transplantation. Transplantation, 2014, 97, 817-825.	1.0	56
53	DIAGNOSTIC UTILITY OF WHOLE BLOOD CYCLOSPORINE MEASUREMENTS IN RENAL TRANSPLANTATION USING TRIPLE THERAPY. Transplantation, 1994, 58, 989-996.	1.0	53
54	Peak Panel Reactive Antibody, Cancer, Graft, and Patient Outcomes in Kidney Transplant Recipients. Transplantation, 2015, 99, 1043-1050.	1.0	53

#	Article	IF	Citations
55	Time on Dialysis and Cancer Risk After Kidney Transplantation. Transplantation, 2013, 95, 114-121.	1.0	51
56	The Expectations and Attitudes of Patients With Chronic Kidney Disease Toward Living Kidney Donor Transplantation. Transplantation, 2015, 99, 540-554.	1.0	51
57	Post-transplant Pneumocystis jirovecii pneumoniaâ€"a re-emerged public health problem?. Kidney International, 2013, 84, 240-243.	5.2	50
58	Mycophenolate Versus Azathioprine for Kidney Transplantation. Transplantation, 2012, 94, 152-158.	1.0	49
59	The experiences of commercial kidney donors: thematic synthesis of qualitative research. Transplant International, 2012, 25, 1138-1149.	1.6	49
60	Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin. Transplantation Direct, 2017, 3, e142.	1.6	48
61	Epithelial-to-Mesenchymal Transition in Early Transplant Tubulointerstitial Damage. Journal of the American Society of Nephrology: JASN, 2008, 19, 1571-1583.	6.1	47
62	Perspectives of Older Kidney Transplant Recipients on Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 443-453.	4.5	47
63	Cost-Effectiveness of Colorectal Cancer Screening in Renal Transplant Recipients. Transplantation, 2008, 85, 532-541.	1.0	46
64	Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies. Biology of Blood and Marrow Transplantation, 2013, 19, 1046-1058.	2.0	46
65	Cancer-Specific and All-Cause Mortality in Kidney Transplant Recipients With and Without Previous Cancer. Transplantation, 2015, 99, 2586-2592.	1.0	46
66	Longitudinal analysis of chronic allograft nephropathy: Clinicopathologic correlations. Kidney International, 2005, 68, S108-S112.	5.2	45
67	Public Awareness and Attitudes to Living Organ Donation. Transplantation, 2013, 96, 429-437.	1.0	45
68	â€˜Suspended in a paradoxâ€™-patient attitudes to wait-listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies. Transplant International, 2015, 28, 771-787.	1.6	44
69	Screening for renal cancer in recipients of kidney transplants. Nephrology Dialysis Transplantation, 2011, 26, 1729-1739.	0.7	43
70	Mortality among Younger and Older Recipients of Kidney Transplants from Expanded Criteria Donors Compared with Standard Criteria Donors. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 128-136.	4.5	43
71	Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?. Nephrology Dialysis Transplantation, 2006, 21, 2060-2063.	0.7	39
72	The Health and Economic Impact of Cervical Cancer Screening and Human Papillomavirus Vaccination in Kidney Transplant Recipients. Transplantation, 2009, 87, 1078-1091.	1.0	39

#	Article	IF	Citations
73	Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. The Cochrane Library, 2017, 2017, CD004756.	2.8	38
74	Individualization of immunosuppression: concepts and rationale. Current Opinion in Organ Transplantation, 2008, 13, 604-608.	1.6	36
75	Increased Incidence of Squamous Cell Carcinoma of Eye After Kidney Transplantation. Journal of the National Cancer Institute, 2007, 99, 1340-1342.	6.3	35
76	Identifying Outcomes that Are Important to Living Kidney Donors. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 916-926.	4.5	35
77	Knowledge, beliefs and attitudes of kidney transplant recipients regarding their risk of cancer. Nephrology, 2012, 17, 300-306.	1.6	33
78	Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection?. American Journal of Transplantation, 2019, 19, 132-144.	4.7	33
79	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.7	31
80	The Risk of Cancer in Recipients of Living-Donor, Standard and Expanded Criteria Deceased Donor Kidney Transplants. Transplantation, 2014, 98, 1286-1293.	1.0	31
81	Clinical Utility of Urinary Cytology to Detect BK Viral Nephropathy. Transplantation, 2015, 99, 1715-1722.	1.0	31
82	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. Transplantation Direct, 2016, 2, e79.	1.6	30
83	Research priority setting in organ transplantation: a systematic review. Transplant International, 2017, 30, 327-343.	1.6	30
84	POSTTRANSPLANT CATARACT: LESSONS FROM KIDNEY-PANCREAS TRANSPLANTATION. Transplantation, 2000, 69, 1108-1114.	1.0	30
85	Perspectives of Transplant Physicians and Surgeons on Reimbursement, Compensation, and Incentives for LivingÂKidney Donors. American Journal of Kidney Diseases, 2014, 64, 622-632.	1.9	29
86	The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation. Transplantation Direct, 2016, 2, e120.	1.6	29
87	Death from cancer: a sobering truth for patients with kidney transplants. Kidney International, 2014, 85, 1262-1264.	5.2	28
88	Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies. American Journal of Kidney Diseases, 2017, 69, 602-616.	1.9	28
89	Transcriptome Changes of Chronic Tubulointerstitial Damage in Early Kidney Transplantation. Transplantation, 2010, 89, 537-547.	1.0	27
90	Detection of chronic allograft nephropathy by quantitative doppler imaging. Transplantation, 2002, 74, 90-96.	1.0	26

#	Article	IF	Citations
91	Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. Transplantation, 2018, 102, 2065-2071.	1.0	26
92	Cost-Effectiveness of Breast Cancer Screening in Women on Dialysis. American Journal of Kidney Diseases, 2008, 52, 916-929.	1.9	25
93	Do protocol transplant biopsies improve kidney transplant outcomes?. Current Opinion in Nephrology and Hypertension, 2012, 21, 580-586.	2.0	25
94	â€˜I feel stronger and younger all the timeâ€™â€”perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research. Nephrology Dialysis Transplantation, 2016, 31, 1531-1540.	0.7	25
95	The Lived Experience of â€œBeing Evaluatedâ€•for Organ Donation. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1852-1861.	4.5	25
96	Health-Related Quality of Life in People Across the Spectrum of CKD. Kidney International Reports, 2020, 5, 2264-2274.	0.8	25
97	Renal transplant outcomes and de novo donor-specific anti-human leukocyte antigen antibodies: a systematic review. Nephrology Dialysis Transplantation, 2018, 33, 1472-1480.	0.7	24
98	Patient experiences of training and transition to home haemodialysis: A mixed-methods study. Nephrology, 2017, 22, 631-641.	1.6	22
99	Interleukin 2 receptor antagonists for kidney transplant recipients. , 2004, , CD003897.		21
100	Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. , 2006, , CD004756.		21
101	Reported cancer screening practices of nephrologists: results from a national survey. Nephrology Dialysis Transplantation, 2009, 24, 2136-2143.	0.7	21
102	Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies. Nephrology Dialysis Transplantation, 2008, 23, 2467-2473.	0.7	20
103	Renal transplantation: better fat than thin. Journal of Surgical Research, 2015, 194, 644-652.	1.6	19
104	One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study). Journal of the American Society of Nephrology: JASN, 2019, 30, 1061-1072.	6.1	19
105	Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 755-764.	0.7	19
106	Chronic allograft nephropathy â€“ a clinical syndrome: early detection and the potential role of proliferation signal inhibitors. Clinical Transplantation, 2009, 23, 769-777.	1.6	18
107	Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant. Nephrology Dialysis Transplantation, 2013, 28, 917-926.	0.7	18
108	CLINICAL DETERMINANTS OF GLUCOSE HOMEOSTASIS AFTER PANCREAS TRANSPLANTATION. Transplantation, 1996, 61, 1705-1711.	1.0	18

#	Article	IF	Citations
109	Public Attitudes and Beliefs About Living Kidney Donation. Transplantation, 2014, 97, 977-985.	1.0	17
110	Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. The Cochrane Library, 2019, 12, CD004290.	2.8	17
111	Progress in Transplantation: Will It Be Achieved in Big Steps or by Marginal Gains?. American Journal of Kidney Diseases, 2017, 69, 287-295.	1.9	15
112	Relative survival and quality of life benefits of pancreasâ€“kidney transplantation, deceased kidney transplantation and dialysis in type 1 diabetes mellitusâ€”a probabilistic simulation model. Transplant International, 2020, 33, 1393-1404.	1.6	15
113	Induction of Allogeneic Islet Tolerance in a Large-Animal Model. Cell Transplantation, 2000, 9, 877-887.	2.5	14
114	Why Do Patients Develop Proteinuria With Sirolimus? Do We Have the Answer?. American Journal of Kidney Diseases, 2010, 55, 213-216.	1.9	14
115	Principles and strategies for involving patients in research in chronic kidney disease: report from national workshops. Nephrology Dialysis Transplantation, 2020, 35, 1585-1594.	0.7	14
116	The consequences of successful transplantation. Lancet, The, 2011, 378, 1357-1359.	13.7	13
117	Expectations and Experiences of Follow-up and Self-Care After Living Kidney Donation. Transplantation, 2017, 101, 2627-2635.	1.0	12
118	Adenine Phosphoribosyltransferase Deficiency: A Potentially Reversible Cause of CKD. Kidney International Reports, 2019, 4, 1161-1170.	0.8	12
119	The Relative Benefits and Costs of Solid Phase Bead Technology to Detect Preformed Donor Specific Antihuman Leukocyte Antigen Antibodies in Determining Suitability for Kidney Transplantation. Transplantation, 2015, 99, 957-964.	1.0	11
120	The potential role of xenogeneic antigenâ€presenting cells in Tâ€cell coâ€stimulation. Xenotransplantation, 1996, 3, 141-148.	2.8	10
121	Successful obstetric outcome after simultaneous pancreas and kidney transplantation. Medical Journal of Australia, 1999, 170, 368-370.	1.7	10
122	Kidney donation and transplantation in Australia: more than a supply and demand equation. Medical Journal of Australia, 2018, 209, 242-243.	1.7	9
123	Organ Transplantation in China. Transplantation, 2015, 99, 1312-1313.	1.0	8
124	Survival and Quality of Life Impact of a Risk-based Allocation Algorithm for Deceased Donor Kidney Transplantation. Transplantation, 2018, 102, 1530-1537.	1.0	8
125	Informative for Decision Making? The Spectrum and Consistency of Outcomes After Living Kidney Donation Reported in Trials and Observational Studies. Transplantation, 2019, 103, 284-290.	1.0	8
126	Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 549-560.	1.9	8

#	Article	IF	Citations
127	Mercaptoacetyltriglycine diuretic renography and output efficiency measurement in renal transplant patients. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 152-154.	6.4	7
128	Care of Transplant Recipients in Primary Practice. Transplantation, 2016, 100, 474-476.	1.0	7
129	Maternal compared with paternal donor kidneys are associated with poorer graft outcomes after kidney transplantation. Kidney International, 2016, 89, 659-665.	5.2	7
130	Integrative Analysis of Prognostic Biomarkers for Acute Rejection in Kidney Transplant Recipients. Transplantation, 2021, 105, 1225-1237.	1.0	7
131	Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol. BMC Public Health, 2011, 11, 516.	2.9	6
132	How is Health Economics Relevant to Transplant Clinicians?. Transplantation, 2014, 98, 124-130.	1.0	6
133	Cliniciansâ€™ attitudes and approaches to evaluating the potential living kidney donorâ€recipient relationship: An interview study. Nephrology, 2019, 24, 252-262.	1.6	6
134	Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?. Transplant Infectious Disease, 2017, 19, e12631.	1.7	5
135	The Pathophysiology and Impact of Inflammation in Nonscarred Renal Interstitium: The Banff i Lesion. Transplantation, 2020, 104, 835-846.	1.0	5
136	Cumulative Doses of T-Cell Depleting Antibody and Cancer Risk after Kidney Transplantation. PLoS ONE, 2015, 10, e0139479.	2.5	5
137	Assessment of renal function after kidney transplantation. Transplantation Reviews, 1996, 10, 138-149.	2.9	4
138	Seeking to Close the Loopholes in Transplant Tourism and Organ Trafficking. Transplantation, 2018, 102, 11-12.	1.0	4
139	Marginal kidneys for transplantation. BMJ, The, 2015, 351, h3856.	6.0	3
140	Despite the Best Intentions Cancer Is Transmissible by Transplantation. Transplantation, 2012, 94, 1185-1186.	1.0	2
141	Cancer in patients with inherited ciliopathies: polycystic kidney disease. Lancet Oncology, The, 2016, 17, 1343-1345.	10.7	2
142	Setting the limit for living kidney donationâ€"how big is too big?. Kidney International, 2017, 91, 534-536.	5.2	2
143	Nonutilization of Kidneys From Donors After Circulatory Determinant of Death. Transplantation Direct, 2022, 8, e1331.	1.6	2
144	A DIFFERENT VIEW OF SENSITIZATION AFTER RENAL TRANSPLANT REJECTION?. Transplantation, 2001, 71, 825-826.	1.0	1

#	Article	IF	Citations
145	Not All Donors Are Equal. Transplantation, 2006, 81, 976-977.	1.0	1
146	Introduction: Targets for Improving Outcomes in Renal Allografts Transplanted During the Next Ten Years. Transplantation, 2008, 85, S1-S2.	1.0	1
147	Autosomal dominant polycystic kidney disease (ADPKD) is associated with coronary arterial dilatation in end-stage renal failure patients. CKJ: Clinical Kidney Journal, 2012, 5, 41-43.	2.9	1
148	Donor-derived Diseaseâ€"Who to Notify?. Transplantation, 2021, 105, 1909-1910.	1.0	1
149	The IDEAL trial in Australia and New Zealand: clinical and economic impact. Nephrology Dialysis Transplantation, 2021, 37, 168-174.	0.7	1
150	The Recipient of a Renal Transplant. , 2008, , 48-63.		1
151	Simultaneous pancreas and kidney transplantation: a review of outcome from a single center. Hong Kong Journal of Nephrology, 1999, 1, 11-17.	0.0	0
152	Commentary: Harmonizing the Regulators. Transplantation, 2005, 79, 638.	1.0	0
153	Not that day â€¦. Medical Journal of Australia, 2009, 191, 613-614.	1.7	0
154	Reply to â€œReview of Living Kidney Donor Guidelines is Out of Date Before Publicationâ€• Transplantation, 2012, 93, e18-e19.	1.0	0
155	Balancing sensitivity and specificity - unfolding crossmatch biology in renal transplantation*. Transplant International, 2012, 25, 1129-1130.	1.6	0
156	Are Nonesterified Fatty Acids Protective in Chronic Allograft Nephropathy?. Transplantation, 2013, 95, 1313-1314.	1.0	0
157	China and the organ trade. Medical Journal of Australia, 2013, 199, 728-728.	1.7	0
158	Professor Bruce Hall and the ABC. Medical Journal of Australia, 2014, 201, 322-322.	1.7	0
159	Buyer beware transplantation. Kidney International, 2016, 89, 983-985.	5.2	0
160	The Recipient of a Renal Transplant. , 2019, , 51-68.		0
161	Management Guidelines Peritransplantation. , 2009, , 341-363.		0
162	The Recipient of a Kidney Transplant. , 2014, , 54-71.		0